Education
About Us
Working with TipRanks
Follow Us
Gland Pharma Ltd. (IN:GLAND)
:GLAND
RESEARCH TOOLSreports
GLAND Analyst Ratings
Moderate Sell
0 Buy
0 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GLAND Stock 12 Month Forecast
Average Price Target
₹1,602.50
▼(-20.47%Downside)
| Highest Price Target₹1,680 | Average Price Target₹1,603 | Lowest Price Target₹1,525 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
₹2,054
Hold
1.94%
Upside
07/08/25
Gland Pharma Ltd. scores well due to its robust financial performance, marked by consistent revenue growth and solid balance sheet metrics. However, technical indicators suggest caution due to potential overbought conditions, and valuation metrics indicate the stock may be overvalued at current levels.
Citi
₹1,420→₹1,680
Sell
-16.62%
Downside
Reiterated
07/22/25
Goldman Sachs
₹1,400→₹1,525
Sell
-24.31%
Downside
Reiterated
07/15/25
Nomura
₹1,790→₹1,570
Hold
-22.08%
Downside
Reiterated
02/07/25
Investec
₹2,055→₹1,750
Buy
-13.14%
Downside
Reiterated
02/04/25
Jefferies
₹1,630→₹1,350
Sell
-33.00%
Downside
Reiterated
02/04/25
Bank of America Securities
₹2,080→₹2,020
Buy
0.26%
Upside
Reiterated
02/04/25
Kotak Mahindra
₹1,625
Sell
-19.35%
Downside
Reiterated
12/27/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
₹2,054
Hold
1.94%
Upside
07/08/25
Gland Pharma Ltd. scores well due to its robust financial performance, marked by consistent revenue growth and solid balance sheet metrics. However, technical indicators suggest caution due to potential overbought conditions, and valuation metrics indicate the stock may be overvalued at current levels.
Citi
₹1,420→₹1,680
Sell
-16.62%
Downside
Reiterated
07/22/25
Goldman Sachs
₹1,400→₹1,525
Sell
-24.31%
Downside
Reiterated
07/15/25
Nomura
₹1,790→₹1,570
Hold
-22.08%
Downside
Reiterated
02/07/25
Investec
₹2,055→₹1,750
Buy
-13.14%
Downside
Reiterated
02/04/25
Jefferies
₹1,630→₹1,350
Sell
-33.00%
Downside
Reiterated
02/04/25
Bank of America Securities
₹2,080→₹2,020
Buy
0.26%
Upside
Reiterated
02/04/25
Kotak Mahindra
₹1,625
Sell
-19.35%
Downside
Reiterated
12/27/24
Best Analysts Covering Gland Pharma Ltd.
1 Month
xxx
Success Rate
1/2 ratings generated profit
Average Return
+6.40%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +6.40% per trade.
3 Months
xxx
Success Rate
2/2 ratings generated profit
Average Return
+12.85%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +12.85% per trade.
1 Year
Success Rate
0/2 ratings generated profit
Average Return
-25.35%
reiterated a sell rating 6 months ago
Copying Alok Dalal's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -25.35% per trade.
2 Years
xxx
Success Rate
0/2 ratings generated profit
Average Return
-25.35%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -25.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GLAND Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
0
2
2
2
0
Hold
1
2
2
1
5
Sell
3
5
5
4
4
Strong Sell
0
0
0
0
0
total
4
9
9
7
9
Each month's total comprises the sum of three months' worth of ratings.
GLAND Financial Forecast
GLAND Stock Forecast FAQ
What is IN:GLAND’s average 12-month price target, according to analysts?
Based on analyst ratings, Gland Pharma Ltd.’s 12-month average price target is 1,602.50.
What is IN:GLAND’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IN:GLAND, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Gland Pharma Ltd. a Buy, Sell or Hold?
Gland Pharma Ltd. has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 0 hold ratings and 2 sell ratings.
What is Gland Pharma Ltd.’s share price target?
The average share price target for Gland Pharma Ltd. is 1,602.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹1,680.00 ,and the lowest forecast is ₹1,525.00. The average share price target represents -20.47% Decrease from the current price of ₹2,014.85.
The highest analyst share price target is ₹1,680.00 ,and the lowest forecast is ₹1,525.00. The average share price target represents -20.47% Decrease from the current price of ₹2,014.85.
What do analysts say about Gland Pharma Ltd.?
Gland Pharma Ltd.’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of Gland Pharma Ltd.?
To buy shares of IN:GLAND, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.